Previous close | 1,428.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 10,174,882 |
Market cap | 58.893B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 12.96 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.61 (4.33%) |
Ex-dividend date | 23 Feb 2023 |
1y target est | N/A |
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
PHILADELPHIA, December 11, 2022--GSK plc (LSE/NYSE:GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patients previously treated with an approved Janus kinase (JAK) inhibitor. Additionally, new analyses from MOMENTUM showed
PHILADELPHIA, August 08, 2022--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus